Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Taiwan
/
Pharmaceuticals & Biotech
/
Lotus Pharmaceutical
1795
Lotus Pharmaceutical
Hybrid Pipeline Expansion Will Harness Aging Trends Amid Cost Headwinds
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
01 Aug 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
NT$600.00
66.6% undervalued
intrinsic discount
09 Aug
NT$200.50
Loading
1Y
-27.1%
7D
-9.5%
Author's Valuation
NT$600.0
66.6% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
NT$600.0
66.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-307m
24b
2014
2017
2020
2023
2025
2026
2028
Revenue NT$24.0b
Earnings NT$5.2b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.78%
Pharma revenue growth rate
1.09%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.17%
Calculation
NT$5.15b
Earnings '28
x
35.51x
PE Ratio '28
=
NT$182.86b
Market Cap '28
NT$182.86b
Market Cap '28
/
266.24m
No. shares '28
=
NT$686.84
Share Price '28
NT$686.84
Share Price '28
Discounted to 2025 @ 5.17% p.a.
=
NT$590.45
Fair Value '25